(Q33853472)

29 July 2017

1 reference

title

Dapsone: unapproved uses or indications (English)

1 reference

29 July 2017

1 reference

Wolf R

1

1 reference

29 July 2017

Tüzün B

series ordinal

2

1 reference

29 July 2017

Tüzün Y

series ordinal

3

1 reference

29 July 2017

publication date

1 January 2000

1 reference

29 July 2017

published in

Clinics in Dermatology

1 reference

29 July 2017

volume

18

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

37-53

1 reference

The story of sulfones in tropical medicine and dermatology

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

1 reference

7 January 2021

New approaches to chemotherapy for leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone-trimethoprim for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Sulfonamides and sulfones in dermatologic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Sulfones and sulfonamides in dermatology today

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Sulfapyridine and Sulfone Type Drugs in Dermatology

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dermatitis herpetiformis and linear IgA bullous dermatosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Treatment and management of dermatitis herpetiformis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

The treatment of dermatitis herpetiformis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Derivate desp-Nitrothiophenols

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

THE TREATMENT OF STREPTOCOCCAL INFECTIONS IN MICE WITH 4:4'DIAMINODIPHENYLSULPHONE

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Sulfozone (diasone) sodium for dermatitis herpetiformis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Clinical pharmacokinetics of dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone Acetylation and the Treatment of Leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo*

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

The treatment of acne vulgaris with dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

The sulfone syndrome complicated by pancreatitis and pleural effusion in an adolescent receiving dapsone for treatment of acne vulgaris

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Successful treatment of acute dapsone intoxication using charcoal hemoperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone hypersensitivity. The sulfone syndrome revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone-induced peripheral neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Acne therapy. Medication use and sources of care in office-based practice

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Erythema nodosum and circulating immune complexes in acne fulminans after treatment with isotretinoin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Eruptive pyogenic granulomas and acne fulminans in two siblings treated with isotretinoin. A possible common pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Acne fulminans and 13-cis-retinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Acne fulminans and erythema nodosum during isotretinoin therapy responding to dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

1 reference

7 January 2021

Behçet's disease and complex aphthosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Suppression of Behçet's disease with dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Behçet's disease in South African blacks: report of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Behçet's disease. Report of twenty-five patients from the United States with prominent mucocutaneous involvement

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

1 reference

7 January 2021

Sulfapyridine in the treatment of dermatitis herpetiformis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dermatitis herpetiformis; specific entity or clinical complex

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Pemphigus and pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Bullous pemphigoid controlled by Dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Bullous pemphigoid in childhood: report of three cases and a review of literature

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Granular deposits of immunoglobulins in the skin of patients with dermatitis herpetiformis. An immunofluorescent study

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Diagnostic significance of the immunofluorescent pattern in dermatitis herpetiformis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Letter: Bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Bullous Pemphigoid Responding to Sulfapyridine and the Sulfones

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone as first line therapy for bullous pemphigoid.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Adjuvant therapy of bullous pemphigoid with dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Lack of predictive factors for the clinical course of bullous pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Treatment of bullous pemphigoid with topical clobetasol propionate

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Systemic chemotherapy for ocular cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone therapy for the acute inflammatory phase of ocular pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Long-term results of systemic chemotherapy for ocular cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Sulphapyridine--a new agent for the treatment of ocular cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Oral pemphigoid. Subset of cicatricial pemphigoid?

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Cicatricial pemphigoid: diagnosis and treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Cicatricial pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone and sulfapyridine therapy of pemphigoid diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Epidermolysis bullosa acquisita and bullous systemic lupus erythematosus. Diseases of autoimmunity to type VII collagen.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Childhood epidermolysis bullosa acquisita

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Childhood acquired epidermolysis bullosa

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Epidermolysis bullosa acquisita in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Epidermolysis bullosa acquisita in a 6-year-old Japanese boy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Successful treatment of epidermolysis bullosa acquisita using intravenous immunoglobulins.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Epidermolysis bullosa acquisita--successful treatment with colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Epidermolysis bullosa acquisita: clinical response to plasma exchange therapy and circulating anti-basement membrane zone antibody titer

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Erythema elevatum diutinum: A clinical and histopathologic study of 13 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Erythema elevatum diutinum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Association of hyperimmunoglobulinaemia D syndrome with erythema elevatum diutinum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

[Erythema elevatum diutinum. A rare dermatosis with a broad spectrum of associated illnesses]

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Erythema elevatum diutinum in human immunodeficiency virus-infected patients--report of a case and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Erythema elevatum diutinum. Response to dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Erythema elevatum diutinum: an unusual reaction to streptococcal antigen and response to dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Erythema elevatum diutinum--vesicular lesions and sulphone response

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Peripheral ulcerative keratitis associated with erythema elevatum diutinum and a positive rheumatoid factor: a report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Erythema elevatum diutinum: a clinicopathological study

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Unusual erythema elevatum diutinum with fibrohistiocytic proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Regression of Kaposi's sarcoma in AIDS after treatment with dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone for AIDS-associated Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dermatitis herpetiformis: an evaluation of diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Immunoelectronmicroscopic localization of IgA in skin of patients with dermatitis herpetiformis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Bullous pemphigoid, herpes gestationis and linear dermatitis herpetiformis: circulating anti-basement membrane zone antibodies; in vitro studies

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Unusual Subepidermal Bullous Diseases With Immunologic Features of Bullous Pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Polymorphic Pemphigoid

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

IgA linear dermatosis of childhood (chronic Bullous disease of childhood)

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Small intestinal biopsies and HLA types in dermatitis herpetiformis patients with granular and linear IgA skin deposits

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Long term follow-up of dermatitis herpetiformis with and without dietary gluten withdrawal

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Linear IgA bullous dermatosis of adults

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

When and how to use sulfones in bullous diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Drug-induced linear IgA bullous dermatosis: report of six cases and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Depot sulfonamid associated linear IgA bullous dermatosis with erythema multiforme-like clinical features

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Chronic bullous disease of childhood and linear IgA disease of adults are IgA1-mediated diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Linear IgA bullous dermatosis of adults and children: an immunoelectron microscopic study

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Linear IgA bullous dermatosis of childhood (Chronic bullous dermatosis of childhood)

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

The course of chronic bullous disease of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

The treatment of benign chronic bullous dermatosis of childhood, and dermatitis herpetiformis and bullous pemphigoid beginning in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Chronic bullous disease of childhood--aspects of management

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Chronic bullous dermatosis of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Chronic bullous disease of childhood in three patients of Polynesian extraction

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Chronic urticaria-like lesions in systemic lupus erythematosus. A review of 12 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Urticaria-like lesions associated with systemic lupus erythematosus: response to dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Systemic lupus erythematosus and vasculitic urticaria. Effect of dapsone and complement levels

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Bullous eruption of systemic lupus erythematosus: a clinicopathological study of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Vesiculobullous systemic lupus erythematosus. A report of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Annular subacute cutaneous lupus erythematosus responsive to dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Thrombocytopenia in systemic lupus erythematosus responsive to dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone in the treatment of cutaneous lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone in the treatment of lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone and discoid lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Clinical and pathologic correlations in 96 patients with panniculitis, including 15 patients with deficient levels of alpha 1-antitrypsin

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Panniculitis associated with severe alpha 1-antitrypsin deficiency. Treatment and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Alpha-1-antitrypsin deficiency panniculitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Alpha1-Antitrypsin Deficiency-Associated Panniculitis: Case Report and Review of the Literature

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

[Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapsone therapy]

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Pyoderma gangrenosum; a clinical study of nineteen cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Pyoderma gangrenosum with an unusual syndrome of ulcers, vesicles, and arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Pyoderma gangrenosum in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Bilateral pyoderma gangrenosum of the hand: treatment with dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Diaminodiphenylsulfone and steroids in the treatment of pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

1 reference

7 January 2021

Malignant pyoderma or pyoderma gangrenosum of the head and neck?

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Malignant pyoderma: a clinical variant of pyoderma gangrenosum

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Relapsing polychondritis treated with dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Treatment of relapsing polychondritis with dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Relapsing polychondritis--report of ten cases

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Relapsing polychondritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Relapsing polychondritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Immune complex-mediated renal involvement in relapsing polychondritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Cyclosporin A Treatment in a Case of Relapsing Polychondritis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Relapsing polychondritis in an adolescent

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Therapy of brown spider envenomation: a controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone or electric shock therapy of brown recluse spider envenomation?

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Brown recluse spider envenomation of the eyelid: an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Brown recluse spider bites of the upper extremity

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

The diagnosis and treatment of brown recluse spider bites

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Clinical presentation and outcome of brown recluse spider bite

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Acute arthropod envenomation. Incidence, clinical features and management

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Loxosceles reclusa envenomation

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Stings and bites. Tips on coexisting comfortably with the insects.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

1 reference

7 January 2021

Spiders and spider bites.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Images in clinical medicine. Loxoscelism

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Spider bites in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

SUBCORNEAL PUSTULAR DERMATOSIS

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Subcorneal pustular dermatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Subcorneal pustular dermatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Subcorneal pustular dermatosis is not pustular psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Urticarial vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Sustained dapsone-induced remission of hypocomplementemic urticarial vasculitis--a case report.

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

The normocomplementemic urticarial vasculitis syndrome‐report of a case and response to colchicine

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Cutaneous small-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Current therapies for systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

1 reference

7 January 2021

Tissue destruction by neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Assay of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Granulocyte-Mediated Release of Histamine from Mast Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Superoxide is an antagonist of antiinflammatory drugs that inhibit hypochlorous acid production by myeloperoxidase

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system. A possible correlation with their anti-inflammatory properties

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dermatitis herpetiformis: Effects of sulfones and sulfonamides on neutrophil myeloperoxidase-mediated iodination and cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Anti-inflammatory actions of dapsone and its related biochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dissociation of the inhibitory effect of dapsone on the generation of oxygen intermediates—in comparision with that of colchicine and various scavengers

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Inhibition of neutrophil adherence to antibody by dapsone: a possible therapeutic mechanism of dapsone in the treatment of IgA dermatoses

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone inhibits LTB4 binding and bioresponse at the cellular and physiologic levels

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Dapsone Suppresses Integrin-Mediated Neutrophil Adherence Function

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

Anti-inflammatory action of dapsone: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0738-081X%2899%2900093-0

7 January 2021

10.1016/S0738-081X(99)00093-0

Identifiers

DOI

1 reference

release_32mluolpzfa5tlflqt22ppbeve

29 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/32mluolpzfa5tlflqt22ppbeve

24 November 2022

mapped directly with Wikidata item

1 reference